Senores Pharmaceuticals Limited has informed the Exchange regarding submission of Reconciliation of Share Capital Audit Report for the quarter ended December 31, 2025
SENORES · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Senores Pharmaceuticals has filed its quarterly Reconciliation of Share Capital Audit Report with the stock exchanges for the quarter ended December 31, 2025, as required under SEBI Regulation 76. The audit was carried out by Mr. Tapan Shah, a practicing Company Secretary, and was signed on January 7, 2026. The report confirms that the company's share capital position matches records held with NSDL, CDSL, and in physical form, with no discrepancies reported. As additional disclosure, the company secretary noted that Senores has entered into a Share Purchase Agreement to acquire 100% of Apnar Pharma Private Limited, which would make Apnar a wholly-owned subsidiary once the deal closes. The filing was submitted to both NSE (symbol: SENORES) and BSE (scrip code: 544319).
This is a routine quarterly compliance filing and is unlikely to move the stock on its own. However, the attached note about the pending acquisition of Apnar Pharma Private Limited is worth tracking, as completing the deal would add a wholly-owned subsidiary to Senores' business.